{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T20:25:11Z","timestamp":1779395111588,"version":"3.53.1"},"reference-count":96,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.atherosclerosis.2009.11.033","type":"journal-article","created":{"date-parts":[[2009,11,28]],"date-time":"2009-11-28T09:16:31Z","timestamp":1259399791000},"page":"337-343","source":"Crossref","is-referenced-by-count":104,"title":["The genetics of statin-induced myopathy"],"prefix":"10.1016","volume":"210","author":[{"given":"Abhijit","family":"Ghatak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Faheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2796.2006.01700.x","article-title":"Who should receive a statin these days? Lessons from recent clinical trials","volume":"260","author":"Shepherd","year":"2006","journal-title":"J Intern Med"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib2","doi-asserted-by":"crossref","first-page":"69C","DOI":"10.1016\/j.amjcard.2005.12.013","article-title":"An assessment of statin safety by muscle experts","volume":"97","author":"Thompson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib3","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.amjmed.2003.10.033","article-title":"Current overview of statin-induced myopathy","volume":"116","author":"Rosenson","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ecl.2008.11.002","article-title":"Managing statin myopathy","volume":"38","author":"Venero","year":"2009","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","author":"Draeger","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib9","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1586\/14779072.6.7.971","article-title":"Statin myopathy as a metabolic muscle disease","volume":"6","author":"Phillips","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib11","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1194\/jlr.M600301-JLR200","article-title":"Effects of lipoprotein lipase and statins on cholesterol uptake into heart and skeletal muscle","volume":"48","author":"Yokoyama","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","article-title":"High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial","volume":"78","author":"Paiva","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib13","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1161\/01.ATV.0000190608.28704.71","article-title":"Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins","volume":"25","author":"Urso","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib14","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/art.22100","article-title":"In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects","volume":"55","author":"Guis","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib15","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(04)15739-5","article-title":"Selenoprotein synthesis and side-effects of statins","volume":"363","author":"Moosmann","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","article-title":"Genetic risk factors associated with lipid-lowering drug-induced myopathies","volume":"34","author":"Vladutiu","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/00003088-199732050-00005","article-title":"Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences","volume":"32","author":"Lennernas","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib19","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jclinepi.2006.11.006","article-title":"Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population","volume":"60","author":"McClure","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib20","doi-asserted-by":"crossref","first-page":"44C","DOI":"10.1016\/j.amjcard.2005.12.009","article-title":"Statin safety: lessons from new drug applications for marketed statins","volume":"97","author":"Jacobson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib21","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":"Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin","volume":"82","author":"Pasanen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00210-006-0040-y","article-title":"Pharmacogenomics of human OATP transporters","volume":"372","author":"Konig","year":"2006","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib23","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid","volume":"16","author":"Pasanen","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib24","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1124\/dmd.108.020594","article-title":"Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds","volume":"36","author":"Chen","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clpt.2006.06.010","article-title":"SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin","volume":"80","author":"Niemi","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.fpc.0000114750.08559.32","article-title":"High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)","volume":"14","author":"Niemi","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2133\/dmpk.19.453","article-title":"A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy","volume":"19","author":"Morimoto","year":"2004","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib28","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/01.fpc.0000170913.73780.5f","article-title":"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells","volume":"15","author":"Kameyama","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib29","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1*5 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00008571-199206000-00003","article-title":"Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites","volume":"2","author":"Butler","year":"1992","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003088-200241050-00003","article-title":"Pharmacokinetic\u2013pharmacodynamic drug interactions with HMG-CoA reductase inhibitors","volume":"41","author":"Williams","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)66238-1","article-title":"Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?","volume":"350","author":"Nordin","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00008571-199706000-00004","article-title":"Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution","volume":"7","author":"Marez","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib34","doi-asserted-by":"crossref","first-page":"11825","DOI":"10.1073\/pnas.90.24.11825","article-title":"Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine","volume":"90","author":"Johansson","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib35","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0022-3565(25)10669-1","article-title":"Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis","volume":"274","author":"Dahl","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib36","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1067\/mcp.2001.120251","article-title":"Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin","volume":"70","author":"Mulder","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib37","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1177\/0091270004268128","article-title":"Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms","volume":"44","author":"Kim","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.phrs.2006.12.009","article-title":"Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin","volume":"55","author":"Zuccaro","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib39","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins(1) (2)","volume":"40","author":"Pasternak","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1044-0305(98)00118-4","article-title":"Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma","volume":"10","author":"Bullen","year":"1999","journal-title":"J Am Soc Mass Spectrom"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01213011-200506000-00007","article-title":"Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage","volume":"15","author":"Wilke","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib42","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s10038-004-0188-6","article-title":"A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin","volume":"49","author":"Ishikawa","year":"2004","journal-title":"J Hum Genet"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s002280050094","article-title":"In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors","volume":"50","author":"Transon","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib44","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.2165\/00003495-200262140-00008","article-title":"Rosuvastatin","volume":"62","author":"Carswell","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib45","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1020656607497","article-title":"Novel statins: pharmacological and clinical results","volume":"16","author":"Bolego","year":"2002","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib46","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.RES.83.5.490","article-title":"3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture","volume":"83","author":"Guijarro","year":"1998","journal-title":"Circ Res"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib47","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2217\/14622416.6.8.865","article-title":"Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis","volume":"6","author":"Ruano","year":"2005","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib48","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1172\/JCI38618","article-title":"NO more muscle fatigue","volume":"119","author":"Heydemann","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/03009740410006989","article-title":"The influence of the 5-HT3 receptor antagonist tropisetron on pain in fibromyalgia: a functional magnetic resonance imaging pilot study","author":"Koeppe","year":"2004","journal-title":"Scand J Rheumatol Suppl"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib50","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mus.20871","article-title":"Physiogenomic association of statin-related myalgia to serotonin receptors","volume":"36","author":"Ruano","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib51","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<641::AID-MUS25>3.0.CO;2-M","article-title":"McArdle's disease presenting with asymmetric, late-onset arm weakness","volume":"23","author":"Wolfe","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib52","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1590\/S0004-282X2007000500020","article-title":"McArdle disease with rhabdomyolysis induced by rosuvastatin: case report","volume":"65","author":"Lorenzoni","year":"2007","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib53","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1258\/0004563041201554","article-title":"McArdle's disease diagnosed following statin-induced myositis","volume":"41","author":"Livingstone","year":"2004","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib54","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1258\/000456303322326542","article-title":"The case of stainless statins","volume":"40","author":"Barth","year":"2003","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib55","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2796.2005.01515.x","article-title":"Statin-disclosed acid maltase deficiency","volume":"258","author":"Voermans","year":"2005","journal-title":"J Intern Med"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib56","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jns.2007.09.015","article-title":"Clinical features and new molecular findings in Carnitine Palmitoyltransferase II (CPT II) deficiency","volume":"266","author":"Corti","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib57","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1006\/mgme.1999.2938","article-title":"Carnitine palmitoyltransferase deficiencies","volume":"68","author":"Bonnefont","year":"1999","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib58","series-title":"Harrison's principles of internal medicine","year":"2009"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib59","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.mam.2004.06.004","article-title":"Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects","volume":"25","author":"Bonnefont","year":"2004","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib60","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/BF02522982","article-title":"The effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibition on tissue levels of carnitine and carnitine acyltransferase activity in the rabbit","volume":"31","author":"Bhuiyan","year":"1996","journal-title":"Lipids"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib61","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ana.410440124","article-title":"Genetic characteristics of myoadenylate deaminase deficiency","volume":"44","author":"Verzijl","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib62","doi-asserted-by":"crossref","first-page":"6457","DOI":"10.1073\/pnas.89.14.6457","article-title":"Molecular basis of AMP deaminase deficiency in skeletal muscle","volume":"89","author":"Morisaki","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib63","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1469-7793.2001.t01-1-00881.x","article-title":"Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans","volume":"533","author":"Tarnopolsky","year":"2001","journal-title":"J Physiol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib64","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/348651a0","article-title":"A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies","volume":"348","author":"Goto","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib65","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/0925-4439(91)90042-8","article-title":"A new mtDNA mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS)","volume":"1097","author":"Goto","year":"1991","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib66","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/(SICI)1097-4598(199612)19:12<1603::AID-MUS10>3.0.CO;2-S","article-title":"The 3260 mutation in mitochondrial DNA can cause mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS)","volume":"19","author":"Nishino","year":"1996","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib67","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000101287","article-title":"Statins provoking MELAS syndrome. A case report","volume":"57","author":"Thomas","year":"2007","journal-title":"Eur Neurol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib68","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0002-9343(93)90129-D","article-title":"Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome","volume":"94","author":"Chariot","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib69","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.pediatrneurol.2008.09.002","article-title":"Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation","volume":"39","author":"Tay","year":"2008","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib70","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0002-9440(10)65100-0","article-title":"Mitochondrial DNA depletion syndrome is expressed in amniotic fluid cell cultures","volume":"155","author":"Blake","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib71","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/sj.clpt.6100124","article-title":"Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin","volume":"81","author":"Schick","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib72","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib73","series-title":"American College of Rheumatology 2004 Meeting (Abstract 1784)","article-title":"Metabolic muscle disorders and cholesterol-lowering drugs","author":"Vladitu","year":"2004"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib74","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1086\/500092","article-title":"A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency","volume":"78","author":"Quinzii","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib75","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-6-7","article-title":"Genetic determinants of statin intolerance","volume":"6","author":"Oh","year":"2007","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib76","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/ard.2007.075523","article-title":"Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study","volume":"67","author":"Sailler","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib77","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1006\/bbrc.1994.2112","article-title":"Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors","volume":"202","author":"Nakahara","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib78","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1254\/jphs.93.279","article-title":"Ca2+-releasing effect of cerivastatin on the sarcoplasmic reticulum of mouse and rat skeletal muscle fibers","volume":"93","author":"Inoue","year":"2003","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib79","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.bjp.0704306","article-title":"Properties of Ca(2+) release induced by clofibric acid from the sarcoplasmic reticulum of mouse skeletal muscle fibres","volume":"134","author":"Ikemoto","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib80","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0008-6363(00)00106-1","article-title":"HMG CoA reductase inhibition reduces sarcolemmal Na(+)-K(+) pump density","volume":"47","author":"Gray","year":"2000","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib81","first-page":"258","article-title":"Statin myopathies: pathophysiologic and clinical perspectives","volume":"24","author":"Baker","year":"2001","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib82","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1046\/j.1471-4159.1997.68031142.x","article-title":"Cyclosporin A, an immunosuppressive drug, induces programmed cell death in rat C6 glioma cells by a mechanism that involves the AP-1 transcription factor","volume":"68","author":"Mosieniak","year":"1997","journal-title":"J Neurochem"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib83","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00004311-197917040-00008","article-title":"Epidemiology and inheritance of malignant hyperthermia","volume":"17","author":"Kalow","year":"1979","journal-title":"Int Anesthesiol Clin"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib84","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/0888-7543(91)90084-R","article-title":"A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia","volume":"11","author":"Gillard","year":"1991","journal-title":"Genomics"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib85","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1086\/515454","article-title":"Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle","volume":"60","author":"Monnier","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib86","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/bja\/86.2.283","article-title":"Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia","volume":"86","author":"Urwyler","year":"2001","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib87","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/00003643-200407000-00013","article-title":"Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment","volume":"21","author":"Krivosic-Horber","year":"2004","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib88","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0404.1975.tb07603.x","article-title":"A family with dominant hereditary myotonia, muscular hypertrophy, and increased muscular irritability, distinct from myotonia congenita thomsen","volume":"51","author":"Torbergsen","year":"1975","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib89","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/jnnp.57.3.344","article-title":"Benign familial disease with muscle mounding and rippling","volume":"57","author":"Burns","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib90","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.20350","article-title":"Autosomal recessive rippling muscle disease with homozygous CAV3 mutations","volume":"57","author":"Kubisch","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib91","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/archneur.1996.00550020113023","article-title":"Rippling muscles and myasthenia gravis with rippling muscles","volume":"53","author":"Ansevin","year":"1996","journal-title":"Arch Neurol"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib92","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/ng0498-365","article-title":"Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy","volume":"18","author":"Minetti","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib93","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1006\/geno.1998.5689","article-title":"Physical mapping of the rippling muscle disease locus","volume":"55","author":"Stephan","year":"1999","journal-title":"Genomics"},{"issue":"Suppl. 11","key":"10.1016\/j.atherosclerosis.2009.11.033_bib94","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1002\/mus.10156","article-title":"Rippling muscle disease: a review","author":"Torbergsen","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib95","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/mus.20575","article-title":"Sporadic rippling muscle disease unmasked by simvastatin","volume":"34","author":"Baker","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.atherosclerosis.2009.11.033_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","author":"Grable-Esposito","year":"2009","journal-title":"Muscle Nerve"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915009009903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915009009903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T13:37:39Z","timestamp":1739453859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915009009903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0021915009009903"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.11.033","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}